SCHEDULE 13G/A: BlackRock Discloses 5.2% Passive Stake in Novo Nordisk A/S
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.2% beneficial ownership stake in Novo Nordisk A/S as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 177,801,601 shares of Novo Nordisk A/S Class B Stock.
- This aggregate amount represents 5.2% of the total outstanding Class B Stock of Novo Nordisk A/S.
- BlackRock holds sole voting power over 160,892,571 shares and sole dispositive power over 177,801,601 shares.
- The filing is an Amendment No. 7 to Schedule 13G, indicating a passive investment position under Rule 13d-1(b).
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, inherently neutral in sentiment regarding the issuer's performance, but the presence of a major institutional investor like BlackRock holding a significant stake can be perceived positively by the market.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% of a company's voting stock with a passive investment intent. BlackRock's filing indicates a significant, non-controlling stake in Novo Nordisk, a major pharmaceutical company, reflecting its portfolio allocation strategy and confidence in the long-term prospects of the issuer within the healthcare sector.
Stakeholder Impact
- Shareholders: BlackRock's significant stake makes it a major shareholder, potentially influencing long-term stability and governance through its voting power, albeit passively.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previously revoked Power of Attorney. |
| 01/21/2025 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| 03/31/2025 | Date of the event which required the filing of this statement (reporting period end). |
| 04/23/2025 | Date of signature and filing of the Schedule 13G Amendment No. 7. |
Keywords
Novo Nordisk, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Pharmaceuticals, Healthcare, Investment Management, Class B Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.